Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, London, WC1N 3BG, UK.
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Acta Neuropathol Commun. 2019 Feb 20;7(1):24. doi: 10.1186/s40478-019-0668-8.
The introduction of the classification of brain tumours based on their DNA methylation profile has significantly changed the diagnostic approach for cases with ambiguous histology, non-informative or contradictory molecular profiles or for entities where methylation profiling provides useful information for patient risk stratification, for example in medulloblastoma and ependymoma. We present our experience that combines a conventional molecular diagnostic approach with the complementary use of a DNA methylation-based classification tool, for adult brain tumours originating from local as well as national referrals. We report the frequency of IDH mutations in a large cohort of nearly 1550 patients, EGFR amplifications in almost 1900 IDH-wildtype glioblastomas, and histone mutations in 70 adult gliomas. We demonstrate how additional methylation-based classification has changed and improved our diagnostic approach. Of the 325 cases referred for methylome testing, 179 (56%) had a calibrated score of 0.84 and higher and were included in the evaluation. In these 179 samples, the diagnosis was changed in 45 (25%), refined in 86 (48%) and confirmed in 44 cases (25%). In addition, the methylation arrays contain copy number information that usefully complements the methylation profile. For example, EGFR amplification which is 95% concordant with our Real-Time PCR-based copy number assays. We propose here a diagnostic algorithm that integrates histology, conventional molecular tests and methylation arrays.
基于 DNA 甲基化谱的脑肿瘤分类的引入,显著改变了具有模棱两可的组织学、无信息或矛盾的分子谱的病例,或者对于那些甲基化谱为患者风险分层提供有用信息的实体的诊断方法,例如在髓母细胞瘤和室管膜瘤中。我们介绍了我们的经验,该经验结合了传统的分子诊断方法和互补使用基于 DNA 甲基化的分类工具,用于来自本地和全国转诊的成人脑肿瘤。我们报告了 IDH 突变在近 1550 例患者的大队列中的频率,EGFR 扩增在近 1900 例 IDH 野生型胶质母细胞瘤中,以及在 70 例成人胶质瘤中的组蛋白突变。我们展示了额外的基于甲基化的分类如何改变和改进我们的诊断方法。在 325 例接受甲基组学检测的病例中,有 179 例(56%)的校准评分达到 0.84 及更高,被纳入评估。在这 179 个样本中,45 个(25%)的诊断发生了改变,86 个(48%)的诊断得到了细化,44 个(25%)的诊断得到了证实。此外,甲基化芯片包含有用的拷贝数信息,补充了甲基化谱。例如,EGFR 扩增与我们基于实时 PCR 的拷贝数测定 95%一致。我们在这里提出了一种诊断算法,该算法集成了组织学、常规分子测试和甲基化芯片。